EQS-News: Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom
Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.
- Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.
- Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures.
- Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
- We look forward to supporting the company towards the further clinical validation of its platform.”